







المؤتمر الثالث عشر لإتحاد الأطباء العرب لجمعيات العلوم العصبية 13th Congress of The Pan Arab Union of Neurological Societies

in Conjunction with The Annual Meeting of

THE EGYPTIAN SOCIETY OF NEUROLOGY, PSYCHIATRY & NEUROSURGERY

14th - 17th February, 2013



Sharm El-Sheikh, International Convention Center

Egypt



Welcome Message







Dear Colleagues

The congress of Pan Arab Union of Neurological Societies (PAUNS) is the most important scientific event of Arab neurological world. This 13th congress will be held in Sharm El-Sheikh International Congress Center, Egypt, 14th to 17th February 2013 in conjunction with 14th Cairo International Neurology, Conference of the Egyptian Society of Neurology, Psychiatry and Neurosurgery.

The plenary sessions are dedicated to CVA, Dementia, Polyneuropathies, Epilepsy, Neurophysiology, Vnovement Disorders, Headache, Neurogenetics, Infectious Diseases, VNS, Pediatric Neurology, and other important topics.

The invited speakers are national and international opinion leaders in their fields and scientific literature. The neurologists from all over the world will be able to present their papers as platform or/and poster presentation. All conferences of PAUNS are under the auspices of the WFN and EFNS.

We welcome you to the most exciting and rewarding neurological congress in Egypt, Arab world and the Middle East.

Welcome to recent developments in neurology Welcome to Egypt Welcome to Sharm El-Sheikh

Ahmed Khalifa

President of PAUNS

Mohamed S. El-Tamawy

President of 13th PAUNS Congress

A. Almamun Sarhan

President of E.S.N.P.N



Committees

(President of the Congress)

M. S. El-Tamawy (Egypt)

Honorary Committee (past presidents of PAUNS)

S. Al-Deeb (KSA)
S. Hashem (Egypt)
A. Etribi (Egypt)
M. Malibary (KSA)
R. Gouider (Tunisia)

PAUNS Board

President Vice Presidents

A.Khalifa (Syria) O. Abdulghani (Egypt)

A. Misk (Palestine)

Ch. Mhiri (Tunisia)

S. Bohleega (KSA)

Secretary General Treasurer

M.S. El-Tamawy (Egypt) Abdulnaser Sleie (Syria)

ESNPN Board

President Honorary President

Abdallah Almamun Sarhan Prof. El-Bahy Reda

Vice Presidents Secretary General

Mohamed Saad Shehab Al-Din Prof. Mohamed Osama Abdulghani

Sherif Hamdy

Assist. Secretaries Treasurer

Maged Abdel-Naseer Prof. Hany Amin Aref

Mohamed Safwat Ibrahim

Amal Tawfik Khafagy

Scientific Committee

(All Names Arranged Alphabetically by Family Name)

O. Abdulghani, (Egyp	t). H. N. El-Tallawy	. (Egypt), R. Guidar, (Tunisia)	(Chairpersons)
----------------------	----------------------	-------------------------	----------	----------------

M. Abdel Naseer	(Egypt)	N. Habib	(Libya)
A. Al- Jishi	(Bahrain)	Sh. Hamdy	(Egypt)
M. Arezki	(Algeria)	M. Jomaa	(KSA)
H. Awn	(Yemen)	A. Ezzahi Kacem	(Tunisia)
H. El- Hail	(Qatar)	K. Kallab	(Lebanon)
A. El-Shubili	(Kuwait)	A. Misk	(Palestine)
A. El-Taher	(Sudan)	M. Saadah	(UAE)
T. Farfoti	(Syria)	K. Salem	(Jordan)

Advisory Board

M. Alaoui (Morocco)	J. Inshasi (UAE)
S. Belal (Tunisia)	A . Sabah (Syria)
A. El-Tahan (KSA)	M. Shehab (Jordan)
A. Hamri (Algeria)	O. Sheikh (Sudan)
H. Hosny (Egypt	B.Yamout (Lebanon)

Honorary Presidents of ESNPN

Osama Elwan Farouk Koura Obsis Madkour Sayed El- Gindi Youssef Abo Zeid Esam El-Gengehy Mahmoud Raafat Kandil Abdel Latif Osman Mohamed Montasser Anwar Etribi Mervat Moustafa Mohamed Osman Safva El- Tohamy	Farouk Talaat Saher Hashem Saleh Attya Nadia Hafez Sami El-Shazly Azza El-Mongi Amira Zaki A.Diaa El-Anwar Ahmed Talaat Fathi Afifi Laila El-Mosli Ryadh Gouidar Mohamed S. El-Tamawy
Mohamed Montasser Anwar Etribi Mervat Moustafa	Ahmed Talaat Fathi Afifi Laila El-Mosli
Safya El- Tohamy Ashraf Zaitoun Osama Barrada Mahmoud Allam	Mohamed S. El-Tamawy Hamdy N. El-Tallawy Ayman Youssef Ezeddin Eassa



Arab And International Speakers

"All names are arranged alphabetically by family name"

Imen Abid	©	Tunisia	Abbashar Hussein		Sudan
Ammar E M Ahmed		Sudan	Ahmad Khalifa		Syria
David Bates		UK	Serdar Kocer		France
Nadia Ben Ali	©	Tunisia	Jean-Marc Leger		France
Shakya Bhattacharjee		Ireland	Mariem Meselmani	O	Tunisia
Saeed Bohlega	3	KSA	Xavier Montalban	***	Spain
Carsten G. Bönnemann		USA	Ammar Mubaiden		Jordan
I. Bouchhima	(e)	Tunisia	Afra Musa		Sudan
Enas Ibrahim Darmun		Libya	Ichizo Nishino	1	Japan
Jacques L. De Reuck		Belgium	Ikuya Nonaka	1	Japan
Florian Deisenhammer	7	Austria	Yesim Parman	C	Turkey
Andy Dowson		UK	Francesco Patti		Italy
Ziad El-Chami	34	KSA	Maja Relja		Croatia
Giles Elrington		UK	Peter Rieckmann		UK
Asmahan El-Shobaily		Kuwait	Mohamed Saadah		UAE
Halim Fadil	\$ 1 m	KSA	Mehri Salari		Iran
Mostafa El Alaoui Faris	*	Morocco	Johann Sellner		Germany
Najiba Fekih-Mrissa	©	Tunisia	Raad Shakir		UK
J. Finsterer	7	Austria	Abdelhakim Shawki		KSA
Nathan B. Fountain		USA	Youssef Sidhom	©	Tunisia
Riyadh Gouidar	(e)	Tunisia	Slim Smaoui	©	Tunisia
Werner Hacke		Germany	Bassem Yamout		Lebanon
Richard Hughes		UK	Mehmet Zarifoglu	C	Turkey

Congress Office

Misr 2000 Medical Conferences



Address: 2 El-Gabal El Akhdar Bldg Nasr City - Cairo, Egypt

Tel: +20 (2)23426450 - 23425013 - Fax: 20 (2) 23420344 - 23422549 - Mob: +2 0100 1634534

 $\textbf{E-Mail: khalid@misr2000online.net-misr_2000@hotmail.com}\\$

Website: www.misr2000online.net- www.facebook.com/misr2000

Medical Sponsor Companies

Organizing committee gratefully acknowledges the support and contributions of the following companies, without whom this congress would not be possible.



































































General information & Conditions

Date:

The Congress will be held from 14th - 17th February 2013.

Venue:

The Congress will take place at the MARITIM Sharm El Sheikh International Congress Center which is ideally located in UM Marikha Bay, Peace Road, Sharm El-Sheikh, South Sinai - Egypt.





Badge:

Name is provided with your registration document upon arrival at the Congress center.

For security and regulation purposes, wearing the badge is compulsory at all times both inside the congress center and at all official events organized within the context of the congress.

Please remember: your badge contains encoded details of your registration; you will be asked to show it at each meeting room entrance.

Congress Bags: (counter at Exhibition area) upon presentation of the corresponding voucher











Official Language:

The official language of the congress is English.

A certificate of attendance:

Will be handed over to all pre-registration and on-site registration attendees.

Exhibition:

- The exhibition is open to all registered attendees.
- It is a comprehensive showcase of the latest developments in the pharmaceutical field, technology and equipment, in addition to being a unique opportunity for learning, information sharing and networking.
- To guide them through the exhibition, participants will find inside the congress bag, a very practical exhibition directory in which contact details and profile for each exhibition company are listed.

Exhibitor's Stand Preparation & Display of Exhibits

Tuesday - Wednesday 12th -13th February 2013

11:00 am -11:30 pm

Exhibition Official Opening Hours

Thursday	14 th February 2013	04:00 pm – 09:00 pm
Friday	15 th February 2013	09:00 am - 06:00 pm
Saturday	16th February 2013	09:00 am - 06:00 pm
Sunday	17 th February 2013	09:00 am - 01:00 pm

Removal of Exhibits/Dismantling of Stands

Sunday	17 th February 2013	01:00 pm - 03:00 pm

Mobile phone

- Use of mobile phone is strictly prohibited within scientific session hall.
- Please ensure you have your mobiles switched-off when attending a session.



Recording

• Audio and Video recording is prohibited during the sessions.



Photos

- Photos will be taken during the sessions, events and within the exhibition.
- The pictures will be displayed and can be bought.



PAPERLESS SCIENTIFIC PROGRAM AND DAILY NEWS – Smart phone and online application.

• Scan the code with your Smartphone




Scan QR Code www.Pauns2013.com



Booths Number

Booth No.	Company Name
1	Amer Group
2	Meda Pharmaceuticals
3	Pfizer
4	New Bridge Pharmaceuticals
5-6	Merck Serono
7	Terumo
8	Inspire Pharma
9	Habib Scientific Office
10	Mash Premiere
11	Delta Pharma
12	Allergan
13-14	Novartis
15	Lundbeck
16	APEX-Multiapex Pharma
17	Otsuka
18-20	Biologix FZCO
21-22	Bayer Health Care
23	Quintiles Egypt LLC
24	B.P. Pharma
26	Conference Bags
27	Al Andalous Medical Company
28	El Hayatt Pharma
29	Ranbaxy
30	AstraZeneca
31	Hikma Pharma Egypt
32	BIOTECHNOLOGY
33	EPC
36	Cairo Medical





PAUNS

Thursday



Time	Hall	Session	Subject
12:00 - 16:00	Registration Area		Registration
16:00 – 16:30	Exhibition Area		Welcome Reception
16:30 – 17:00	Hall (A)		Opening ceremony
17:00 – 18:30			Coffee break
18:30 - 19:00	Hall (A)		Plenary Session 1
19:00 - 21:00	Hall (A)		Plenary Session 2





12:00 - 16:00	Registration	
(Also open from Friday to Saturday	9:00 to 18:00)	
16:00 - 16:30	Welcome Reception	
16:30 - 17:00	Opening Ceremony	

Prof. Osama Abdulghani	Secretary General, ESNPN
Prof. Mohamed S. El-Tamawy	President of the Conference
Prof. Abdullah Al-Maamoun Sarhan	President, ESNPN
Prof. Xavier Montalban	President, ENS
Prof. Richard Hughes	President, EFNS
Prof. Raad Shaker	Secretary Treasurer General, WFN
Prof. Werner Hacke	Vice-President, WFN
Prof. Ahmed Khalifa	President, PAUNS





Plenary Session 1





Chairpersons:

"All names are arranged alphabetically by family name"

Riyadh Gouidar Richard Hughes Ahmad Khalifa Jean-Marc Leger

Guillain-Barré Syndrome - One hundred years later

Richard Hughes UK 20 min

Update in the management of chronic immune-mediated neuropathies

Jean-Marc Leger France 20 min

Inherited focal neuropathies

Riyadh Gouidar Tunisia 20 min

Central control of eye movements

Ahmad Khalifa Syria 20 min

Discussion 10 min

18:30 – 19:00 Coffee Break

Plenary Session 2





Hall (A)

Time

19:00 - 21:00

Chairpersons:

Carsten G. Bönnemann Saleh Al-Deeb Abdullah Al-Maamoun Sarhan Bassem Yamout

Congenital muscular dystrophies: An update

Carsten G. Bönnemann USA 20 min

Clinical and genetic findings of limb-girdle muscular dystrophies in Saudi Arabia

Saeed Bohlega KSA 20 min

Early diagnosis of laminopathy

Yukiko K. Hayashi Japan 20 min

Diagnosis and treatment of Multiple Sclerosis: Practice guidelines

Bassem Yamout Lebanon 20 min

Early-onset dementia: Demographic and etiologic characteristics of 170 patients


Mostafa El Alaoui Faris Morocco 20 min

Botulinum toxin -A in the treatment of hypersecretory disorders

Asmahan El-Shobaily Kuwait 20 min

Friday









Plenary Session 3

Hall (A)



Chairpersons:

Saeed Bohlega Jacques L. De Reuck Gharib Fawi Nathan B. Fountain

Cerebral amyloid angiopathy

Jacques L. De Reuck Belgium 30 min

New device and drug therapies for epilepsy

Nathan B. Fountain USA 30 min







CNS-infection



Chairpersons:

Asmahan El-Shobaily Mohamed Saad Raad Shakir Mohamed Shehab

Neurocysticercosis

Raad Shakir UK 15 min

Clinical profile and follow up of pediatric neurocysticercosis cases: A study from eastern India

Shakya Bhattacharjee Ireland 15 min

Anti-NMDA receptor encephalitis

Abdelhakim Shawki KSA 15 min

The first documented can West-Nile virus infection in Saudi Arabia

Halim Fadil KSA 15 min







Neuromodulation



Chairpersons:

Jehad Inshasi Eman Khedr Adel Misk Hassan Nassar

Non-pharmacologic management of movement disorders

Serdar Kocer France 15 min

Non-invasive brain stimulation and gait rehabilitation

Nevine El Nahas Egypt 15 min

Neurogenic dysphagia rehabilitation: A neurologist's perspective

Tamer Emara Egypt 15 min

Cognitive impairment in brain injuries

Karim Ashraf Egypt 15 min

12:00 – 12:30 Coffee Break



PAUNS







Chairpersons:

Azza Abbas Helmy Hassan Hosny Abbashar Hussein Amira Zaki

Mitochondrial Epilepsy in pediatric and adult patients

J. Finsterer Austria 15 min

Epilepsy among elderly sudanese patients

Abbashar Hussein Sudan 15 min

Vagus nerve stimulation: Tunisian clinical experience in drug-resistant epilepsy

Nadia Ben Ali Tunisia 15 min

First Seizure: When to treat?

Hasaan Hosny Egypt 15 min





Novartis Symposium



MS Therapy, New Era





Chairpersons:

Adel El-Geeshy Xavier Montalban Farouk Talaat Magd Fouad Zakaria

Efficacy and safety long-term data on fingolimod

Xavier Montalban Spain 30 min

Growing evidence for the benefit-risk profile of treatment with fingolimod

Magd Fouad Zakaria Egypt 15 min

Discussion 15 min


14:30 - 16:00 Lunch

14:30 - 16:00

(Business meeting of ESNPN council)

(مجلس ادارة الجمعية المصريه للأمراض العصبية والنفسية وجراحة الأعصاب)

Siwa Hall









Dementia and Parkinson's disease



Chairpersons:

Ahmed Diaa El-Anwar Abd El-Fattah El-Qirsh Aroua Ezzahi Mostafa Faris Nadia Hafez

Novel concepts in pathogenesis and management of Alzheimer dementia

Gharib Fawi Egypt 15 min

Rasagiline in Parkinson's disease: Revisiting selective MAO inhibitors

Ossama Abdulghani Egypt 15 min

Role of MRI Brain in differentiating parkinsonian diseases

Ali Shalash Egypt 15 min

Can rTMS help on-freezers with advanced PD?

Hatem Samir Egypt 15 min







Free communications



Chairpersons:

Ann A. Abdel Kader Saleh Attia Sofian Ben-Ammo Samy Shazly Ashraf Zaytoun

Psychogenic non-epileptic seizures semiology: is it an international language?

Ann A. Abdel Kader Egypt 10 min

Neuromyelitis Optica Spectrum Disorders (NMOSD)

Ayman Nassef Egypt 10 min

The use of rituximab for treatment of neuromyelitis optica

Ahmed Nemr Egypt 10 min

What is MR neurography

Rashad Hamdi Egypt 10 min

Dry beriberi mimicking Guillain-Barré syndrome as the first presenting sign of thiamine deficiency

Youssef Sidhom Tunisia 10 min

Discussion 10 min







Neuro-intervention



Chairpersons:

Azza El-Mongue M. Ezzat Elwan Obsis Madkour O'sheikh Mohamed Tarkhan

An Ideal candidate for thrombolysis

Hany Zakieldine Egypt 15 min

Intra-arterial thrombolytic therapy in the setting of ischemic stroke without angiographic vessel occlusion: Single center experience

Ossama Yassin Mansour Egypt 15 min

Analysis of collateral circulation by conventional angiography in cerebral steno-occlusive diseases

Ahmed El-Bassiouny Egypt 15 min

Endovascular therapy of small intracranial aneurysms: A retrospective study

Mostafa Saleh Melake Egypt 15 min







Free communications



Chairpersons:

Samir Belal Hamdy N. El-Talawy Ammar Mubaiden Abdelhakim Shawki

Peripheral versus central vertigo

Ammar Mubaiden Jordan 20 min

Novel crystalloid oligodendrogliopathy in complex hereditary spastic paraplegia

J. Finsterer Austria 10 min

Neurological disorders of cobalamin and folate deficiency: A study of 33 cases.

I. Bouchhima Tunisia 10 min

The role of trace elements in Multiple Sclerosis pathogenesis: A case - control study

Mehri Salari Iran 10 min

Combined estimation of plasma cell-free DNA level and neuron specific enolase as outcome predictors of post-resuscitation patients

Khaled Sallam Egypt 10 min

Saturday



Time	Hall	Session	Subject
09:00 - 10:00	Hall (A)		Plenary Session 4
10:00 - 11:00	Hall (A)	Session 9	Plasma Exchange in Clinical Practice
11:00 – 12:00	Hall (A)	Session 10	Allergan-Sponsored Symposium
12:00 - 12:30		Coffee break	
12:30 - 13:30	Hall (A)	Session 11	Stroke
12:30 - 13:30	Exhibition Area	Poster Session 1	
13:30 – 14:30	Hall (A)	Session 12	"Adapting treatment selection to the patient needs in MS (Biologix and Biogen Idec)"
14:30 - 16:00		Lunch	
14:30 – 16:00	Siwa Hall		Business Meeting of the PAUNS Delegates
16:00 – 17:00	Hall (A)	Session 13	Diseases of Muscles&Neuromuscular Junction
16:00 – 17:00	Hall (B)	Session 14	BOTOX® in Chronic Migraine: Tackling Pain Head-On (Allergan-Sponsored Symposium)
17:00 – 18:30	Hall (A)	Session 15	MS Chapter Session
17:00 – 18:30	Hall (B)	Session 16	Free communications
18:30 - 19:00	Hall (A)		General Assembly of ESNPN
21:00	Summit Hall		Gala Dinner





Plenary Session 4





Chairpersons:

Yousef Abu Zaid Ahmed Azab Werner Hacke Sherif Hamdy

The changing spectrum of neurology

Werner Hacke Germany 20 min

Exploring therapeutic advances in MS

David Bates UK 20 min

Treating mobility impairment in MS

Florian Deisenhammer Austria 20 min









Plasma Exchange in Clinical Practice





Chairpersons:

Maged Abd El-Naseer M. Raafat Kandil Mohamed Safwat Johann Sellner

Role of plasma exchange in neurology: A review of recent literature and guidelines

Johann Sellner Germany 40 Min

Discussion 20 min









BOTOX® for Chronic Migraine: An Innovative Treatment for a Disabling Headache Condition



Sponsored Symposium



Chairpersons:

Giles Elrington Mohamed S. El-Tamawy Hisham Own Amal Tawfik

Welcome and Introduction

Mohamed El-Tamawy Egypt 5 min

Chronic migraine disease pathophysiology and burden of illness

Giles Elrington UK 10 min

Recognizing the chronic migraine patient in practice

Mehmet Zarifoglu Turkey 10 min

BOTOX® for the treatment of chronic migraine: the PREEMPT studies

Maja Relja Croatia 20 min

Panel Discussion 15 min

12:00 – 12:30 Coffee Break

Official Satellite Symposium of the 13th Congress of the Pan-Arab Union of Neurological Societies

BOTOX® for Chronic Migraine: An Innovative Treatment for a Disabling

Headache Condition

AGENDA

11:00 Welcome and Introduction

11:05 Chronic Migraine Disease Pathophysiology and Burden of Illness

Giles Elrington (UK)

11:15 **Recognising the Chronic Migraine Patient in Practice**

Mehmet Zarifoglu (Turkey)

BOTOX® for the Treatment of Chronic Migraine: 11:25

the PREEMPT Studies Maja Relja (Croatia)

11:45 **Panel Discussion**

12:00 Meeting Summary and Close

> Time: 11:00-12:00 Chair: Mohamed El-Tamawy (Egypt)



BOTOX® (botulinum toxin type A) Chronic Migraine **Abbreviated Prescribing Information**

Date: Saturday 16 February 2013

Location: Sinai (Main Ball Room 1)

Presentation: Botulinum toxin type A (from clostridium botulinum) 100 Allergan Units/vial. Indications: To reduce the symptoms of chronic migraine in adults (headaches on 15 days or more days each month of which at least 8 days are with migraine and who have responded inadequalety or are intolerant of preventive migraine medications). Dosage and Administration: See Summary of Product Characteristics or Package Leaflet for full information. Reconstitute with sterile unpreserved normal saline (0.9% sodium chloride for injection). Doses recommended for BOTOX® are not interchangeable with other preparations of botulinum toxin. Inject using 30 gauge, 0.5 inch needle, or 1 inch needle for thicker muscles in neck region if required. Inject 0.1ml (5U) intramuscularly to 31 (up to 39) injection sites, divided across seven specific head/ neck muscle areas including frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles. Inject bilaterally, with the exception of procerus. Total dose 155U-195U. Contra-indications: Known hypersensitivity to any constituent. Pregnancy or lactation. Presence of infection at proposed injection site(s). Warnings/ Precautions: Relevant anatomy and changes due to prior surgical procedures must be understood prior to administration. Adrenaline and other anti-anaphylactic measures should be available. Reports of side effects related to spread of toxin distant from injection site, sometimes resulting in death. Caution in patients with underlying neurological disorder and history of dysphagia and aspiration. Patients should seek medical help if swallowing, speech or respiratory disorders arise. Clinical fluctuations may occur during repeated use. Too frequent or excessive dosing can lead to antibody formation and treatment resistance. Caution

in the presence of inflammation at injection site(s) or when excessive weakness/atrophy is present in target muscle. Caution when used for treatment of patients with peripheral motor neuropathic disease. Use with extreme caution and close supervision in patients with defective neuromuscular transmission (myasthenia gravis, Eaton Lambert Syndrome). Contains human serum albumin. Procedure related injury could occur. Efficacy has not been shown in prophylaxis of episodic migraine (headaches <15 days per month). May cause asthenia, muscle weakness, somnolence, dizziness and visual disturbance which could affect driving and operation of machinery. Interactions: Theoretically, effect may be potentiated by aminoglycoside antibiotics or other drugs that interfere with neuromuscular transmission e.a. tubocurarine-type relaxants. Adverse Effects: See Summary of Product Characteristics or Package Leaflet for full information on side effects. General: Usually occur within the first few days following injection and are transient, but rarely persist for several months or longer. Local muscle weakness represents the expected pharmacological action. Localised pain, tenderness and/or bruising may be associated with the injection. Fever and flu syndrome have been reported. Frequency defined as follows: Very Common (≥ 1/10); Common (≥1/100 <1/10); Uncommon (>1/1,000 to <1/100); Rare $\{ \ge 1/10,000 \text{ to } < 1/1,000 \}; Very Rare (< 1/10,000). Common:$ Headache, migraine, facial paresis, eyelid ptosis, pruritis, rash, neck pain, myalgia, musculoskeletal pain, musculoskeletal stiffness, muscle spasms, muscle tightness, muscular weakness, injection site pain. Uncommon: pain of skin, pain in jaw, dysphagia. Additional Information: Side effects related to spread of toxin distant from site of administration reported very rarely (including exaggerated muscle weakness, dysphagia, aspiration/aspiration pneumonia, with

fatal outcome in some cases). Other adverse events reported include dysarthria, abdominal pain, vision blurred, pyrexia, focal facial paralysis, hypoaesthesia, malaise, myalgia, pruritis, hyperhidrosis, diarrhoea, anorexia, hypoacusis, tinnitus, radiculopathy, syncope, myasthenia gravis, erythema multiforme, dermatitis psoriasiform, vomiting and brachial plexopathy. Also, rare reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Rare reports of serious and/or immediate hypersensitivity (including anaphylaxis, serum sickness, urticaria, soft tissue oedema and dyspnoea) associated with $BOTOX^{\tiny{\textcircled{\tiny{0}}}}$ use alone or in conjunction with other agents known to cause similar reaction. Very rare reports of angle closure glaucoma following treatment for blepharospasm. New onset or recurrent seizure occurred rarely in predisposed patients, however relationship to botulinum toxin has not been established. Needle related pain and/or anxiety may result in vasovagal response. Marketing Authorisation Number: 19272/2005. Marketing Authorisation Holder: Allergan Pharmaceuticals Ireland. Date of preparation: August 2011

Further information is available from: Allergan office, 53 street El Sheikh Mohamed Al Nadi, Nasr City, Cairo, Egypt

Adverse events should be reported to Allergan office: Phone: + 20 2 26701780 Fax: + 20 2 6701646 Email address: ghazal_sahar@allergan.com

Symposium organised and funded by







Hall (A)

Stroke



Chairpersons:

Anwar El-Etribi Mariem Meselmani Mervat Moustafa Raed Roghami Ahmed Talaat

Genetic polymorphisms and thrombosis

Mariem Meselmani Tunisia 15 min

The implication of PAI-I and EPC in thrombosis

Najiba Fekih-Mrissa Tunisia 15 min

Assessment of knowledge and practices of primary health care physicians regarding transient ischemic attacks: Ismailia - Egypt

Mohamed E Negm Egypt 15 min

Watershed infarctions and intracranial stenosis in Egyptian stroke patients

Ramez Reda Moustafa Egypt 15 min





Poster Session 1





Chairpersons:

Zuhaeir Al-Kawi Saly El-Khouly Hassan Farwiz Hala Shahin Abd El-Halim Tantawy

Authors should be available for discussion

From 12:30 - 13:30 Saturday 16th Feb. 2013

(A prize will be offered for the best poster assigned by chairpersons)







Adapting treatment selection to the patient needs in MS





Biologix and Biogen Idec



13:30 - 14:30

Chairpersons:

David Bates Florian Deisenhammer Saher Hashem El-Bahy Reda Mohamed Tarkhan

New device for interferon beta IM self-injection

Florian Deisenhammer

Austria

20 min

Risk stratification to get the most out of Natalizumab treatment

David Bates

UK

40 min

14:30 - 16:00

Lunch

Siwa Hall

14:30 - 16:00

(Business Meeting of the PAUNS Delegates)









10 min

Diseases of Muscles and Neuromuscular Junction



Chairpersons:

Fathi Affifi Ammar Ahmed Samya Ashour Laila El-Mously

Vitamin D deficiency myopathy in Egypt and Saudi Arabia

Nagia Aly Fahmy Egypt

Creatine kinase elevation, lactacidemia, and metabolic myopathy in adult patients with diabetes mellitus

J. Finsterer Austria 10 min

Blurring of vision as a sole presentation for myasthenia gravis

Ammar E M Ahmed Sudan 10 min

New variant of myofibrillary myopathy with CNS involvement

Shereen Shalaby Egypt 10 min

Genetic analysis and care standards for Egyptian Duchenne muscular dystrophy patients

Rasha Sharif Egypt 10 min

Concentric needle jitter using different stimulation methods in extensor digitorum communis and orbicularis oculi muscles in healthy subjects and myasthenic patients

Afra Musa Sudan 10 min







BOTOX® in Chronic Migraine: Tackling Pain Head-On



Sponsored Symposium



Chairpersons:

Zaid El-Chami Saher Hashem Maja Relja Mehmet Zarifoglu

Welcome and Introduction to the PREEMPT clinical trial program

Maja Relja Croatia 10 min

BOTOX® in chronic migraine: Evolution of the injection paradigm

Maja Relja Croatia 10 min

How to inject BOTOX® for chronic migraine 40 min

Session Moderators:

Maja Relja Croatia
Hatem Samir Egypt
Ziad El-Chami Ksa
Yesim Parman Turkey
Mehmet Zarifoglu Turkey
Andy Dowson UK
Giles Elrington UK

[&]quot;This is an invitation-only event. Please visit the Allergan BOTOX® Booth to register your attendance"







MS Chapter Session



Chairpersons:

Hany Aref Rashad Hamdy P. Rieckmann Sayed Tag

MS in 30 years

Xavier Montalban

MS management updates, positioning of the interferon's in the MS Guidelines

Peter Rieckmann

UK

30 min

Unanswered questions in MS trials

Magd F. Zakaria

Egypt

15 min

Recent advances in MS imaging

Rashad Hamdy

Egypt

15 min







Free communications



Chairpersons:

Magdy Dahab Enas Darmun Easa El-Sherouky Wael Fadel

Brain decoding

Ahmed Gaber Egypt 15 min

Epilepsy among pregnant women

Magdy Dahab Egypt 15 min

Pachymeningitis revealing Wegener's granulomatosis (Case report)

Slim Smaoui Tunisia 10 min

Etiologic study of optic neuropathy

I. Bouchhima Tunisia 10 min

Retrograde diagnosis of CNS vasculitis (case discussion)

Enas Ibrahim Darmun Libya 10 min

Non-epileptic quantitative parasagittal EEG findings in epileptic patients

Amira M. El Gohary Egypt 10 min

Postoperative antiepileptic drug withdrawal in adults: Long – term seizure outcome

Hossam Ibrahim Maaty Egypt 10 min

Discussion 10 min







General Assembly of ESNPN



الجمعية العم مية لأع 🛭 المصرية للأمراض العصبية والنفسية وجراحة الأعصاب

21:00

Gala Dinner

Sunday 17th Feb

Time	Hall	Session	Subject
09:00 - 10:00	Hall (A)		Plenary Session 5
10:00 - 11:00	Hall (A)	Session 17	Pain & Neurorehabilitation
11:00 – 12:00	Hall (A)	Session 18	Management of Gait Abnormalities (Biologix)
12:00 - 12:30	Hall (A)	Coffee break	
12:30 - 13:30	Hall (A)	Session 19	Neurogenetics
13:30 - 14:30		Session 20	MS Management: A Story of Success (Bayer Schering)
14:30 – 15:30		Lunch	





Plenary Session 5





Chairpersons:

Samiha Abd El-Moneim Y. Hayashi Abd El-Raouf Omar Ikuya Nonaka

Therapeutic approaches to Duchenne muscular dystrophy

Ikuya Nonaka Japan 30 min

Metabolic myopathy

Ichizo Nishino Japan 30 min







Pain & Neurorehabilitation



Chairpersons:

Moshira Darwish Ahmed Osama Mohamed El-Boraie Mohamed Saadah

A strange and forgettable neuropathic pain with its clinicopathologic characters

Mohamed Saadah

UAE

15 min

Botulinum toxin – type A: Could it be an effective treatment option in intractable trigeminal neuralgia?

Nevin Mohieldin Shalaby

Egypt

15 min

Movement-related cortical stimulation can induce human motor plasticity

Mohamed Nasreldin Thabit

Egypt

15 min

Clinical effects of a six-month cognitive training in visual motor integration in Down's syndrome

children: A randomized controlled trial

Faten H. Abdelazeim

Egypt

15 min







Management of Gait Abnormalities



Biologix and Biogen Idec



Chairpersons:

Osama Abdulghani Ayman Ezz El-Din Serdar Kocer Tarek Tawfik

Gait abnormalities in neurological diseases and spasticity management of the lower limb

Serdar Kocer France 45 min

BT-A injections techniques and US guided BT injection

Serdar Kocer France 15 min

12:00 - 12:30

Coffee Break







Neurogenetics



Chairpersons:

Ahmed Deif Shoukry Mihari Mohamed Okda Al-Shoura Yousef

Neuronal ceroid lipofuscinosis in Egypt: A novel mutation in MFSD8 gene

Ahmed Gaber Egypt min 15

L2 hydroxy glutaric aciduria (L2HGA): Phenotypic variability in c.241A \rightarrow G mutation patients

Imen Abid Tunisia min 15

Phenotypic variability among a family with neuroacanthocytosis

Slim Smaoui Tunisia min 15

Discussion 15 min







MS Management: A Story of Success





Chairpersons:

Adel Hassanein Francesco Patti **Mona Raafat** Peter Reckman

Betaferon® 21 years follow up, MS-survival data "Latest results"

Peter Rieckmann UK 30 min

BENEFIT study - Latest results

Francesco Patti 30 min Italy

14:30 - 15:30

Lunch

EGYPT

90 MILLION - PEOPLE POWER

7 THOUSAND YEARS = CULTURE

29 GOVERNORATES - PLACES

2 SEAS - GEOGRAPHY

1 MILLION SQUARE KILOMETERS = SPACE

1 RIVER NILE - LIFE

1 GREAT PYRAMID = GLORY

MISR 2000

Rosetta Damietta

Cairo

Medical Conferences



IAPCO Member In Middle East and Africa

Member since: 2008

Since: 1999

History: Over 400 Event



MEMBER

1 IAPCO PCO = UNIQUE

- Address: 2 El-Gabal El Akhdar Bldg Nasr City Cairo, Egypt
- Tel: +20 (2)23426450 23425013 Fax: 20 (2) 23420344 23422549 Mob: +2 0100 1634534
- E-Mail: khalid@misr2000online.net misr_2000@hotmail.com
- Website: www.misr2000online.net www.facebook.com/misr2000



El Gouna*

Hurghada .

Luxor

Safaga

Scan GR Code www.misr2000coline.net